The abortion pill mifepristone, fresh off the Supreme Court’s ruling to uphold its approval by the Food and Drug Administration, will likely soon face another challenge brought by three states with abortion bans, an opportunity that anti-abortion advocates hope will spur the court to curtail the drug.

In the ruling Thursday in Alliance for Hippocratic Medicine v. FDA, written by Trump-appointed Justice Brett Kavanaugh, the justices found that the group of anti-abortion doctors who brought the suit had not been sufficiently harmed by the FDA’s approval to be able to merit redress.